A method for preparing dibenzo-azo compounds and their intermediates

Moxapramine was prepared by a seven-step reaction using conventional reagents and solvents, simplifying the synthesis process, solving the problems of limited raw material availability and safety, and enabling efficient industrial production.

CN123106676APending Publication Date: 2026-11-17HEFEI OUCHUANG GENE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611360753.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-03
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing moxapramine synthesis routes suffer from limited raw material availability, poor operational safety due to highly toxic reagents, and low overall yield, making industrial-scale production impossible.

Method used

Moxapramine was prepared by a seven-step continuous reaction, including substitution, cyclization, hydrolysis, condensation and acid deprotection. Conventional commercial reagents and solvents were used, and compounds II, III, IV, V and VI were used as intermediates to simplify the synthetic process.

Benefits of technology

It provides a completely new synthetic route for mosapram, which simplifies the process, reduces production costs and time, improves safety, and enriches the originality of the synthetic system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106676A_ABST
    Figure CN123106676A_ABST
Patent Text Reader

Abstract

This invention provides a method for preparing intermediate compound VI, the reaction formula of which is shown below: wherein R1 is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl or pteropentyl; X is selected from Cl, Br, I; R2 is an amino protecting group; the method includes the following steps: Step S1: Compound I reacts with an amino group under alkaline conditions to obtain compound II, where X and X1 are independently selected from Cl, Br, I; Step S2: Compound II undergoes cyclization under alkaline conditions to obtain compound III; Step S3: Compound III undergoes hydrolysis to obtain compound IV; Step S4: Compound IV undergoes condensation reaction with an ammonia source under the action of a catalyst to obtain compound V; Step S5: Compound V is reduced to obtain compound VI.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical organic synthesis technology, specifically relating to a method for preparing dibenzozaspirolactam compounds. Background Technology

[0002] Mosapramine is an antipsychotic drug with a dibenzodiazepine skeleton that works by blocking dopamine D2 receptors and is clinically used to treat schizophrenia. The compound is characterized by the presence of a spirolactam fragment and a piperidine skeleton, and its synthesis involves multiple functional group transformations.

[0003] In the prior art, Yakugaku Zasshi (1989), 109(2), 93-101 has disclosed the preparation process of the conventional compound VII-1 and the basic synthetic route of mosapamine:

[0004]

[0005] Existing synthetic routes for moxapramine suffer from drawbacks such as limited availability of raw materials, poor operational safety due to highly toxic reagents, and low overall yield, making it impossible to obtain the target compound using current techniques. Therefore, it is necessary to develop a moxapramine preparation method that uses readily available raw materials, involves simple steps, and is suitable for industrial-scale production. Summary of the Invention

[0006] The first aspect of this invention provides a method for preparing intermediate compound VI, the reaction formula of which is shown below:

[0007]

[0008] Wherein, R1 is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl or pteropentyl; X is selected from Cl, Br, I, preferably Br; R2 is an amino protecting group;

[0009] R2 is independently selected from one of benzyloxycarbonyl, 9-fluorenoxycarbonyl, tert-butoxycarbonyl, tert-valeryl, acetyl, triphenylmethyl, allyloxycarbonyl, benzyl, trimethylsilylethoxycarbonyl, trichloroethoxycarbonyl, phthaloyl, p-methoxybenzyl, trifluoroacetyl, 2-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl, 2-nitrobenzenesulfonyl, 2-nitrobenzyl, 2-nitrophenylethyl, methanesulfonyl, p-toluenesulfonyl, methoxycarbonyl, or ethoxycarbonyl.

[0010] Includes the following steps:

[0011] Step S1: Compound I and The reaction under alkaline conditions yields compound II, where X and X1 are independently selected from Cl, Br, and I.

[0012] Step S2: Compound II undergoes cyclization under basic conditions to yield compound III;

[0013] Step S3: The hydrolysis of compound III yields compound IV;

[0014] Step S4: Under the action of a catalyst, compound IV undergoes a condensation reaction with an ammonia source to obtain compound V;

[0015] Step S5: Compound V is reduced to obtain compound VI.

[0016] Further, the compound in step S1 Selected from 5-chlorovaleryl chloride, 5-bromovaleryl chloride, and 5-iodovaleryl chloride, with 5-bromovaleryl chloride being preferred;

[0017] Further, the base mentioned in step S1 is selected from at least one of pyridine, triethylamine, diisopropylethylamine (DIPEA), 2-methylpyridine, and 4-dimethylaminopyridine (DMAP); preferably pyridine;

[0018] Further, in step S1, compound I and The molar ratio is 1:1.0~2.0, preferably 1:1.2;

[0019] Further, in step S1, the molar ratio of compound I to the base is 1:2.0~5.0, preferably 1:3.0;

[0020] Further, the reaction in step S1 is carried out in a solvent selected from at least one of dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, toluene, and acetonitrile; preferably dichloromethane;

[0021] Further, the mass-to-volume ratio of compound I to solvent in step S1 is 1:8~12 g / mL, preferably 1:10 g / mL;

[0022] Further, step S1 is selected from a reaction temperature of 0℃~40℃, preferably room temperature of 20~25℃;

[0023] Furthermore, the reaction time in step S1 is 6~24 h, preferably 12~16 h;

[0024] Further, the alkali mentioned in step S2 is selected from at least one of sodium hydride, potassium tert-butoxide, sodium tert-butoxide, and potassium hydride, preferably sodium hydride;

[0025] Further, in step S2, the molar ratio of compound II to base is 1:1.1 to 1.5, preferably 1:1.3;

[0026] Furthermore, in step S2, the material is fed at a low temperature, and after feeding is completed, the mixture is stirred and reacted at room temperature for 8 to 24 hours, preferably 16 hours.

[0027] Furthermore, the reaction temperature in step S2 is -5℃ to 30℃, preferably 25℃;

[0028] Further, step S2 is carried out in a solvent selected from at least one of tetrahydrofuran, 2-methyltetrahydrofuran, and 1,4-dioxane, preferably anhydrous tetrahydrofuran;

[0029] Further, in step S2, the mass-to-volume ratio of compound II to solvent is 1:(7~10) g / mL, preferably 1:8 g / mL;

[0030] Furthermore, the reaction base in step S3 is selected from sodium hydroxide, potassium hydroxide, and lithium hydroxide, with sodium hydroxide being preferred;

[0031] Furthermore, in step S3, the molar ratio of compound III to the base is 1:1 to 45, preferably 1:43;

[0032] Furthermore, the pH of the reaction solution in step S3 is 11-14;

[0033] Further, the reaction in step S3 is carried out in a solvent selected from at least one of methanol, ethanol, and isopropanol, preferably methanol;

[0034] Further, in step S3, the mass-to-volume ratio of compound III to solvent is 1:(8-35) g / mL, preferably 1:33 g / mL;

[0035] Furthermore, the reaction temperature in step S3 is 40–60 °C, preferably 50 °C;

[0036] Furthermore, the reaction time for step S3 is 8–24 h, preferably 16 h;

[0037] Further, the ammonia source in step S4 is selected from ammonium salts, including ammonium chloride, ammonium acetate, ammonium formate, ammonium bicarbonate, ammonium carbonate, and ammonium sulfate; preferably ammonium chloride or ammonium acetate; ammonium chloride is preferred.

[0038] Further, in step S4, the condensing agent is selected from at least one of EDCI, DCC, and HBTU, with EDCI being preferred;

[0039] Furthermore, in step S4, activator HOBt or HOAt may be selectively added, with HOBt being preferred;

[0040] Furthermore, the condensation reagent in step S4 is EDCI / HOBt;

[0041] Further, the catalyst in step S4 is 4-dimethylaminopyridine (DMAP), 4-pyrrolidinylpyridine (4-PPY), or 4-methoxypyridine (MOPY), preferably 4-dimethylaminopyridine (DMAP).

[0042] Further, the molar ratio of compound IV to the ammonia source in step S4 is 1:1.0 to 1.5, preferably 1:1.1;

[0043] Further, the molar ratio of compound IV to condensing agent in step S4 is 1:2.0 to 6.0, preferably 1:3;

[0044] Further, the molar ratio of compound IV to catalyst in step S4 is 1:0.1 to 0.5, preferably 1:0.2;

[0045] Further, step S4 is carried out in a solvent selected from at least one of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), and acetonitrile, preferably N,N-dimethylformamide;

[0046] Furthermore, the mass-to-volume ratio of compound IV to solvent is 1:(8-12) g / mL, preferably 1:10 g / mL;

[0047] Furthermore, the reaction temperature in step S4 is 20℃~35℃, preferably 20~25℃;

[0048] Furthermore, the reaction time for step S4 is 8-16 h, preferably 12 h;

[0049] Further, in step S5, the molar ratio of compound V to the reducing agent is 1:1.0~1.3, preferably 1:1.2;

[0050] Further, the reaction in step S5 is carried out in a solvent, which is selected from at least one of methanol, ethanol, and isopropanol, preferably methanol;

[0051] Further, the reducing agent in step S5 is selected from at least one of sodium borohydride, potassium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride, preferably sodium borohydride;

[0052] Furthermore, the reaction temperature in step S5 is 20–30 °C, preferably room temperature (20–25 °C).

[0053] Furthermore, the reaction time for step S5 is 8 to 24 hours, preferably 16 hours.

[0054] The second aspect of the present invention provides a method for preparing mosapamine, comprising the reaction steps described in the first aspect of the present invention, and further comprising the following synthesis steps 6 and 7, to prepare the target product mosapamine.

[0055]

[0056] X2 is selected from Cl, Br, and I, with Cl being the preferred choice;

[0057] Step S6: Deprotection of compound VI yields compound VII;

[0058] Step S7: Compound VII reacts with compound VIII under alkaline conditions to give compound moxapramine;

[0059] Furthermore, the deprotecting agent mentioned in step S6 is an amino deprotecting agent, and the agent is selected for deprotection according to the specific protecting group;

[0060] Furthermore, when the protecting group in step S6 is tert-butyloxycarbonyl, the deprotecting agent in step S6 is selected from at least one of dioxane hydrochloride solution, methanol hydrochloride solution, trifluoroacetic acid, and acetic acid / hydrochloric acid system;

[0061] Further, the molar ratio of compound VI to the deprotecting agent in step S6 is 1:(8-10), preferably 1:8.33;

[0062] Further, step S6 is carried out in a solvent, which is a mixed solvent of alcohol and haloalkane, selected from at least one of methanol / dichloromethane, ethanol / dichloromethane, and methanol / chloroform mixed systems, preferably methanol / dichloromethane mixed solvent; the volume ratio of alcohol to haloalkane is 1:(0.5~2), preferably 1:1;

[0063] Further, in step S6, the mass-to-volume ratio of compound VI to solvent is 1:(2~10) g / mL, preferably 1:3.3 g / mL;

[0064] Furthermore, the reaction temperature in step S6 is 15~35 ℃, preferably 20~25 ℃;

[0065] Furthermore, the reaction time in step S6 is 1~8 h, preferably 4~5 h;

[0066] Further, in step S7, the base is selected from at least one of cesium carbonate, potassium carbonate, sodium carbonate, and potassium bicarbonate, preferably cesium carbonate;

[0067] Further, in step S7, the molar ratio of compound VII to compound VIII is 1:1.0 to 1.5, preferably 1:1;

[0068] Further, in step S7, the molar ratio of compound VII to the base is 1:1.5~3.0, preferably 1:2;

[0069] Further, step S7 is carried out in a solvent selected from at least one of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), and N-methylpyrrolidone (NMP), preferably N,N-dimethylformamide;

[0070] Further, in step S7, the mass-to-volume ratio of compound VII to solvent is 1:12~18 g / mL, preferably 1:15 g / mL.

[0071] Furthermore, the reaction temperature in step S7 is 100~120 ℃, preferably 110 ℃;

[0072] Furthermore, the reaction time in step S7 is 3 to 6 hours, preferably 4 hours.

[0073] A third aspect of the present invention provides a compound having the structures shown in formulas II, III, IV, V, and VI;

[0074] ;

[0075] In the formula, X, R1, and R2 are as described in the first aspect of the present invention;

[0076] Furthermore, a compound having the structures shown in formulas II-1, III-1, IV-1, V-1, and VI-1 is provided:

[0077] .

[0078] The fourth aspect of this invention provides the use of the above-mentioned compounds II, III, IV, V, and VI in the preparation of dibenzo-azines;

[0079] The fifth aspect of the present invention provides the use of the above-mentioned compounds II-1, III-1, IV-1, V-1, and VI-1 in the preparation of dibenzo-azines;

[0080] The sixth aspect of the present invention provides a method for preparing dibenzodiazepine compounds, the method comprising using the preparation method of compound VI as described in any one of the first aspects of the present invention, further reacting compound VI of the second aspect of the present invention to prepare moxapramine, and / or using II, III, IV, V, and VI as raw materials or intermediates as described in the fourth and fifth aspects of the present invention to further prepare antipsychotic dibenzodiazepine compounds.

[0081] Beneficial technical effects of the present invention:

[0082] 1. Compounds II, III, IV, V, and VI involved in the synthetic route of this invention are all novel structural intermediates that have never been publicly reported in the prior art, and there are no existing technologies to refer to. The above series of novel intermediates provide a completely new preparation idea for the synthetic route of mosapamine drugs, enrich the synthetic system of this type of drug, and have extremely high originality and scientific research value.

[0083] 2. This invention constructs a complete synthetic chain based on a series of novel intermediates, sequentially preparing the target product through seven consecutive reactions: substitution, cyclization, hydrolysis, condensation, acid deprotection, and nucleophilic substitution. Each reaction step is tightly linked and exhibits good process compatibility. The crude intermediates from these steps can be directly used in the next reaction without complex purification operations, significantly simplifying the synthetic process, shortening the production cycle, and reducing intermediate separation losses and preparation costs.

[0084] 3. This invention uses conventional commercial condensing agents, reducing agents, acid and base reagents, and common organic solvents. The raw materials are readily available, the cost is low, and the operation is safe. Attached Figure Description

[0085] Figure 1 Compound II-1 of Example 1 of this invention 1 H NMR spectrum;

[0086] Figure 2 Compound III-1 of Example 2 of this invention 1 H NMR spectrum;

[0087] Figure 3 Compound IV-1 of Example 3 of this invention 1 H NMR spectrum;

[0088] Figure 4 Compound VI-1 of Example 5 of this invention 1 H NMR spectrum. Detailed Implementation

[0089] The preparation method of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0090] Unless otherwise specified, the experimental methods used in the following examples are conventional methods; unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0091] Example 1:

[0092]

[0093] Compound I-1 (2.00 g, 7.70 mmol) and pyridine (1.84 g, 23.2 mmol) were added to a dry 250 mL three-necked flask, followed by 20 mL of anhydrous dichloromethane. The mixture was stirred at room temperature until the solids were completely dissolved. 5-Bromopentanoyl chloride (CAS 4509-9-4, 1.85 g, 9.30 mmol) was slowly added dropwise at 20–25 °C. After the addition was complete, the mixture was stirred at room temperature for 16 h. The reaction mixture was monitored by TLC to ensure complete consumption of the reactants. The reaction solution was washed with 30 mL of saturated sodium bicarbonate solution, and the organic phase was separated. The solution was dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography to give 2.5 g of a clear oil, II-1. The composition of compound II-1... 1 H NMR spectrum as shown Figure 1 As shown.

[0094] The NMR data for compound II-1 are as follows:

[0095] ¹H NMR (400 MHz, CDCl3) δ 5.68 (s, 1H), 3.77 (d, J = 13.9 Hz, 2H), 3.72 (s, 3H), 3.41 (t, J = 6.5 Hz, 2H), 3.19 – 3.11 (m, 2H), 2.25 (t, J = 7.2Hz, 2H), 2.06 (d, J = 9.0 Hz, 2H), 1.98 – 1.87 (m, 4H), 1.82 – 1.76 (m, 2H), 1.45 (s, 9H).

[0096] Example 2:

[0097]

[0098] Compound II-1 (0.62 g, 1.47 mmol) was added to a dry, clean three-necked reaction flask, followed by 5 mL of anhydrous tetrahydrofuran. The mixture was stirred until the solid substrate was completely and evenly dispersed. The system was cooled to 0 °C, and sodium hydride (0.076 g, 1.91 mmol) was slowly added in portions, maintaining the temperature below 5 °C during the addition process to prevent violent exothermic reactions and side reactions. After the addition was complete, the mixture was allowed to warm naturally to room temperature and stirred continuously overnight. After the reaction was complete, deionized water was slowly added dropwise to quench the reaction and completely consume any remaining strong base. After complete quenching, the solvent was removed by rotary evaporation under reduced pressure. The resulting crude product required no further purification and could be used directly in the next reaction step. Compound III-1... 1 H NMR spectrum as shown Figure 2 As shown.

[0099] The NMR data for compound III-1 are as follows:

[0100] ¹H NMR (400 MHz, CDCl3) δ 3.91 (s, 2H), 3.38 (t, J = 5.8 Hz, 2H), 3.33 – 3.24 (m, 1H), 2.56 (t, J = 6.3 Hz, 2H), 2.32 (d, J = 12.4 Hz, 2H), 1.87 (d, J = 3.8 Hz, 2H), 1.82 – 1.76 (m, 3H), 1.48 (s, 9H).

[0101] Example 3:

[0102]

[0103] Compound III-1 (0.15 g, 0.46 mmol) was added to a clean, dry single-necked reaction flask, followed by 5 mL of methanol. The mixture was stirred until the solid was completely dissolved, then 10 mL of a 2 mol / L sodium hydroxide aqueous solution was added. The system was heated to 50 °C and stirred overnight. After the reaction was complete, the system was cooled to room temperature, and the pH of the reaction solution was adjusted to weakly acidic by slow addition of 2 mol / L hydrochloric acid. After adjustment, ethyl acetate was added for multiple extractions. All organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent, finally yielding 0.10 g of a white solid, compound IV-1. The composition of compound IV-1... 1 H NMR spectrum as shown Figure 3 As shown.

[0104] The NMR data for compound IV-1 are as follows:

[0105] ¹H NMR (400 MHz, CDCl3) δ 3.88 (s, 2H), 3.36 (t, J = 5.8Hz, 2H), 3.32– 3.24 (m, 1H), 2.53 (t, J = 6.3 Hz, 2H), 2.29 (d,J = 12.4 Hz, 2H), 1.92 –1.69 (m, 6H), 1.45 (s, 9H), 1.26 (t, J= 7.1 Hz, 2H).

[0106] Example 4:

[0107]

[0108] Compound IV-1 (4.0 g, 12.2 mmol), HOBT (4.95 g, 36.7 mmol), EDCI (7.03 g, 36.7 mmol), DMAP (0.30 g, 2.44 mmol), and ammonium chloride (0.42 g, 13.45 mmol) were added sequentially to a dry and clean reaction flask. Then, 40 mL of anhydrous N,N-dimethylformamide was added. The mixture was stirred thoroughly at room temperature until the solids were completely dissolved, and the reaction was continued overnight with constant stirring. After the reaction was complete, the solvent was removed by rotary evaporation under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a dichloromethane / methanol system (50:1 v / v) to obtain 5.2 g of crude solid. The obtained crude solid was slurried with methanol, thoroughly stirred and washed, and filtered to remove insoluble solid impurities. The filtrate was collected and the methanol solvent was removed by rotary evaporation under reduced pressure, finally yielding 3.8 g of the target product V-1 as a yellow liquid.

[0109] The NMR data for compound V-1 are as follows:

[0110] ¹H NMR (400 MHz, CDCl3) δ 4.01 (s, 2H), 3.62 (s, 2H), 3.20 (t, J =5.7 Hz, 2H), 2.79 (t, J = 6.4 Hz, 2H), 1.99 – 1.91 (m, 2H), 1.85 (dd, J =11.6, 6.4 Hz, 2H), 1.77 (d, J = 11.7 Hz, 2H), 1.54 (d, J = 13.2 Hz, 2H), 1.45(d, J = 4.8 Hz, 9H).

[0111] Example 5:

[0112]

[0113] Compound V-1 (2.0 g, 6.5 mmol) was added to a clean, dry single-necked reaction flask, followed by 20 mL of methanol. The mixture was stirred at room temperature until the solid was completely dissolved. Sodium borohydride (0.30 g, 7.8 mmol) was then added in portions. After the addition was complete, the mixture was stirred at room temperature overnight. After the reaction was complete, 2 mL of deionized water was slowly added to the reaction system to quench any remaining reducing agent. After complete quenching, the solvent was removed by rotary evaporation under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a dichloromethane / methanol system (20:1 v / v) to obtain 1.5 g of a white solid, compound VI-1. The composition of compound VI-1... 1 H NMR spectrum as shown Figure 4 As shown.

[0114] The NMR data for compound VI-1 are as follows:

[0115] ¹H NMR (400 MHz, MeOD) δ 3.94 (dd, J = 23.1, 13.2 Hz, 3H), 3.69 (s,1H), 3.17 (s, 1H), 2.87 – 2.78 (m, 1H), 2.45 (t, J = 11.1 Hz, 1H), 1.93 – 1.76 (m, 3H), 1.73 – 1.50 (m, 5H), 1.46 (s, 9H), 1.44 – 1.23 (m, 3H).

[0116] Example 6:

[0117]

[0118] Compound VI-1 (1.5 g, 4.8 mmol) was added to a dry, clean single-necked reaction flask, followed by 5 mL of a methanol / dichloromethane mixture. The mixture was stirred at room temperature until the solid was completely dissolved. Subsequently, 10 mL of dioxane hydrochloride solution was added, and the reaction was carried out at room temperature with stirring for 5 h. After the reaction was completed, the solvent and volatile impurities were removed by rotary evaporation under reduced pressure. The crude product obtained did not require further purification and was directly used in the next substitution reaction.

[0119] Example 7:

[0120]

[0121] Compound VII-1 (2.0 g, 8.16 mmol), compound VIII-1 (2.5 g, 8.16 mmol), and cesium carbonate (5.3 g, 16.3 mmol) were added sequentially to a dry, clean three-necked reaction flask. Then, 30 mL of N,N-dimethylformamide was added, and the mixture was stirred thoroughly at room temperature until homogeneous. The system was heated to 110 °C and reacted under sealed conditions for 4 h with stirring. After the reaction was complete, heating was stopped, and the system was cooled to room temperature. The DMF solvent was removed by rotary evaporation under reduced pressure to obtain the crude product. The crude product was purified by preparative liquid chromatography to finally obtain 450 mg of the target product, moxapramine, as a yellow solid with an HPLC purity of 98.7%.

[0122] 1HNMR(400 MHz DMSO)6 8.16 (s,1H),7.20-7.03(m, 5H),7.00-6.88 (m, 2H).3.75 (d, J= 9.1Hz, 1H). 3.69 (tJ=6.5 Hz, 2H). 3.05 (s, 4H). 2.74(t.J=9.9 Hz,2H).2.53 (s, 1H).2.46 (s, 1H).2.38-2.10 (m,4H), 1.80-1.65 (m,2H),1.63-1.43(m,6H), 1.42-1.08 (m, 4H).

Claims

1. A process for the preparation of an intermediate compound VI, characterized in that, The reaction formula is shown below: Wherein, R1 is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl, or p-pentyl; X is selected from Cl, Br, or I; R2 is independently selected from benzyloxycarbonyl, 9-fluorenoxycarbonyl, tert-butoxycarbonyl, p-pentylyl, acetyl, triphenylmethyl, allyloxycarbonyl, benzyl, trimethylsilylethoxycarbonyl, trichloroethoxycarbonyl, phthaloyl, p-methoxybenzyl, trifluoroacetyl, 2-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl, 2-nitrobenzenesulfonyl, 2-nitrobenzenesulfonyl, 2-nitrobenzyl, 2-nitrobenzenethyl, methanesulfonyl, p-toluenesulfonyl, methoxycarbonyl, or ethoxycarbonyl. Includes the following steps: Step S1 : Compound I is reacted with Compound II is obtained by reaction under basic conditions, X, X1are independently selected from Cl, Br, I; Step S2: Compound II undergoes cyclization under basic conditions to yield compound III; Step S3: The hydrolysis of compound III yields compound IV; Step S4: Under the action of a catalyst, compound IV undergoes a condensation reaction with an ammonia source to obtain compound V; Step S5: Compound V is reduced to obtain compound VI.

2. The production method according to claim 1, characterized by, Step S1 satisfies at least one of the following conditions: Step S1 compound selected from 5-chlorovaleryl chloride, 5-bromovaleryl chloride, 5-iodovaleryl chloride; The base mentioned in step S1 is selected from at least one of pyridine, triethylamine, diisopropylethylamine, 2-methylpyridine, and 4-dimethylaminopyridine; Step S1 Compound I is reacted with in a molar ratio of 1 : 1.0 to 2.0, preferably 1 : 1.

2. In step S1, the molar ratio of compound I to the base is 1:2.0~5.0, preferably 1:3.0; Step S1 is carried out in a solvent selected from at least one of dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, toluene, and acetonitrile. In step S1, the mass-to-volume ratio of compound I to solvent is 1:8~12 g / mL, preferably 1:10 g / mL; Step S1 is selected from a reaction temperature of 0℃~40℃, preferably room temperature of 20~25℃; The reaction time for step S1 is 6 to 24 hours, preferably 12 to 16 hours.

3. The preparation method according to claim 1, characterized in that, The preparation method described in step S2 satisfies at least one of the following conditions: The alkali mentioned in step S2 is selected from at least one of sodium hydride, potassium tert-butoxide, sodium tert-butoxide, and potassium hydride; In step S2, the molar ratio of compound II to base is 1:1.1 to 1.5, preferably 1:1.3; In step S2, the material is fed at a low temperature. After the feeding is completed, the mixture is stirred and reacted at room temperature for 8 to 24 hours, preferably 16 hours. The reaction temperature in step S2 is -5℃ to 30℃, preferably 25℃; Step S2 is carried out in a solvent selected from at least one of tetrahydrofuran, 2-methyltetrahydrofuran, and 1,4-dioxane; In step S2, the mass-to-volume ratio of compound II to solvent is 1:(7~10) g / mL, preferably 1:8 g / mL.

4. The production method according to claim 1, characterized by, The preparation method described in step S3 satisfies at least one of the following conditions: The preparation method described in step S3 satisfies at least one of the following conditions: The reaction base in step S3 is selected from sodium hydroxide, potassium hydroxide, and lithium hydroxide; In step S3, the molar ratio of compound III to the base is 1:1 to 45, preferably 1:43; The pH of the reaction solution in step S3 is 11-14; Step S3 is carried out in a solvent, which is selected from at least one of methanol, ethanol, and isopropanol, preferably methanol; In step S3, the mass-to-volume ratio of compound III to solvent is 1:(8-35) g / mL, preferably 1:33 g / mL; The reaction temperature in step S3 is 40–60 °C, preferably 50 °C; The reaction time for step S3 is 8 to 24 hours, preferably 16 hours.

5. The preparation method according to claim 1, characterized in that, The preparation method described in step S4 satisfies at least one of the following conditions: The ammonia source in step S4 is selected from ammonium salts, including ammonium chloride, ammonium acetate, ammonium formate, ammonium bicarbonate, ammonium carbonate, and ammonium sulfate; ammonium chloride and ammonium acetate are preferred. The condensing agent in step S4 is selected from at least one of EDCI, DCC, and HBTU, with EDCI being preferred; Step S4: Selectively add activator HOBt and HOAt; The condensation reagent in step S4 is EDCI / HOBt; The catalyst for step S4 is 4-dimethylaminopyridine, 4-pyrrolidinylpyridine, or 4-methoxypyridine; In step S4, the molar ratio of compound IV to the ammonia source is 1:1.0 to 1.5, preferably 1:1.1; In step S4, the molar ratio of compound IV to the condensing agent is 1:2.0 to 6.0, preferably 1:3; In step S4, the molar ratio of compound IV to the catalyst is 1:0.1 to 0.5, preferably 1:0.2; Step S4 is carried out in a solvent selected from at least one of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, and acetonitrile, preferably N,N-dimethylformamide; The mass-to-volume ratio of compound IV to solvent is 1:(8-12) g / mL, preferably 1:10 g / mL; The reaction temperature in step S4 is 20℃~35℃, preferably 20~25℃; The reaction time for step S4 is 8 to 16 hours, preferably 12 hours.

6. The preparation method according to claim 1, characterized in that, The preparation method described in step S5 satisfies at least one of the following conditions: In step S5, the molar ratio of compound V to the reducing agent is 1:1.0~1.3, preferably 1:1.2; Step S5 is carried out in a solvent, which is selected from at least one of methanol, ethanol, and isopropanol, preferably methanol; The reducing agent in step S5 is selected from at least one of sodium borohydride, potassium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride, with sodium borohydride being preferred; The reaction temperature in step S5 is 20–30 °C, preferably room temperature (20–25 °C). The reaction time for step S5 is 8 to 24 hours, preferably 16 hours.

7. A method for preparing mosapram, characterized in that, The method for preparing intermediate compound VI according to any one of claims 1 to 6, further includes the steps S6 and S7: X2 is selected from Cl, Br, and I; Step S6: Deprotection of compound VI yields compound VII; Step S7: Compound VII reacts with compound VIII under alkaline conditions to give compound moxaparin.

8. The preparation method according to claim 6, characterized in that, The preparation methods described in steps S6 and S7 satisfy at least one of the following conditions: The deprotecting agent mentioned in step S6 is an amino deprotecting agent. Different agents are selected for deprotection according to different protecting groups. When the protecting group in step S6 is tert-butyloxycarbonyl, the deprotecting agent in step S6 is selected from at least one of dioxane hydrochloride solution, methanol hydrochloride solution, trifluoroacetic acid, and acetic acid / hydrochloric acid system; In step S6, the molar ratio of compound VI to the deprotecting agent is 1:(8-10), preferably 1:8.33; The reaction in step S6 is carried out in a solvent, which is a mixed solvent of alcohol and haloalkane, selected from at least one of methanol / dichloromethane, ethanol / dichloromethane, and methanol / chloroform mixed systems, preferably methanol / dichloromethane mixed solvent; the volume ratio of alcohol to haloalkane is 1:(0.5~2), preferably 1:1; In step S6, the mass-to-volume ratio of compound VI to solvent is 1:(2~10) g / mL, preferably 1:3.3 g / mL; The reaction temperature in step S6 is 15~35 ℃, preferably 20~25 ℃; The reaction time for step S6 is 1~8 h, preferably 4~5 h; In step S7, the base is selected from at least one of cesium carbonate, potassium carbonate, sodium carbonate, and potassium bicarbonate, with cesium carbonate being preferred. In step S7, the molar ratio of compound VII to compound VIII is 1:1.0~1.5, preferably 1:1; In step S7, the molar ratio of compound VII to the base is 1:1.5~3.0, preferably 1:2; Step S7 is carried out in a solvent selected from at least one of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, and N-methylpyrrolidone. In step S7, the mass-to-volume ratio of compound VII to solvent is 1:12~18 g / mL, preferably 1:15 g / mL. The reaction temperature in step S7 is 100~120 ℃, preferably 110 ℃; The reaction time for step S7 is 3 to 6 hours, preferably 4 hours.

9. A compound having the structures shown in formulas II, III, IV, V, and VI; ; In the formula, X, R1, and R2 are as described in claim 1; Compounds with the preferred structures shown in formulas II-1, III-1, IV-1, V-1, and VI-1: 。 10. A method for preparing dibenzodiazepine compounds, comprising preparing compound VI using the compound as described in claim 9 or the preparation method comprising any one of claims 1 to 6, wherein compound VI is further prepared into an antipsychotic dibenzodiazepine compound.